Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PV Stock Forecast 2025-2026
$2.47
Current Price
$89.42M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PV Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
PV Price Momentum
0.0%
1 Week Change
+11.3%
1 Month Change
+52.5%
1 Year Change
+22.9%
Year-to-Date Change
-7.1%
From 52W High of $2.66
+170.8%
From 52W Low of $0.91
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Primavera Capital (PV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PV and similar high-potential opportunities.
Latest PV Stock Price Targets & Analyst Predictions
PV has shown a year-to-date change of 22.9% and a 1-year change of 52.5%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for PV. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PV Analyst Ratings
0
Buy
0
Hold
0
Sell
PV Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $2.47
Latest PV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Primavera Capital Acquisition Corporation (PV) Competitors
The following stocks are similar to Primavera Capital based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Primavera Capital Acquisition Corporation (PV) Financial Data
Primavera Capital Acquisition Corporation has a market capitalization of $89.42M with a P/E ratio of 30.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +5.5%.
Valuation Metrics
Market Cap
$89.42M
Enterprise Value
$0
P/E Ratio
30.0x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+0.2%
Current Ratio
0.5x
Debt/Equity
0.0x
ROE
+5.5%
ROA
+5.0%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Primavera Capital Acquisition Corporation (PV) Business Model
About Primavera Capital Acquisition Corporation
What They Do
Business Model
Additional Information
Company Information
Primavera Capital Acquisition Corporation (PV) Latest News & Analysis
Latest News
Quick Summary
PharmaEssentia USA announces that the latest NCCN Guidelines endorse BESREMi® (ropeginterferon alfa-2b-njft) as a treatment option, signaling potential growth in its market presence.
Why It Matters
The NCCN guidelines endorsing BESREMi® may boost PharmaEssentia's sales and market position in hematology and oncology, positively impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia's SURPASS-ET trial for ropeginterferon alfa-2b-njft (P1101) in essential thrombocythemia achieved its primary endpoint, demonstrating positive hematologic responses.
Why It Matters
Positive trial results for PharmaEssentia's drug could lead to increased market confidence, potential revenue growth, and stock price appreciation, impacting investor sentiment and decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia has signed an exclusive licensing agreement with FORUS Therapeutics for the registration and distribution of BESREMi® in Canada for treating polycythemia vera.
Why It Matters
The licensing agreement expands PharmaEssentia's market reach for BESREMi® in Canada, potentially increasing revenue and enhancing its position in the hematology sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Germany's grid-connected battery storage capacity may reach 60 GW by 2050, up from current levels, with trends in cost and installation similar to photovoltaics, signaling significant changes in energy supply.
Why It Matters
The projected surge in battery storage capacity signals significant growth in the energy sector, potentially boosting investments in related technologies and companies, while reshaping energy supply dynamics.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia USA announced results from a real-world data review published in the Journal of Clinical Oncology, set to be presented at the 2024 ASCO Annual Meeting.
Why It Matters
PharmaEssentia's real-world data review could indicate the efficacy and market potential of its biologics, influencing investor sentiment and stock performance in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PharmaEssentia USA published an article in the British Journal of Clinical Pharmacology on ropeginterferon alfa-2b treatment for polycythemia, highlighting exposure-efficacy and exposure-safety analyses.
Why It Matters
The publication in a reputable journal highlights PharmaEssentia's advancements in treatment for hematology and oncology, potentially boosting investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PV Stock
What is Primavera Capital Acquisition Corporation's (PV) stock forecast for 2025?
Analyst forecasts for Primavera Capital Acquisition Corporation (PV) are not currently available. The stock is trading at $2.47.
Is PV stock a good investment in 2025?
Analyst ratings for PV are not currently available. The stock is currently trading at $2.47. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PV stock?
Price predictions from Wall Street analysts for PV are not currently available. The stock is trading at $2.47.
What is Primavera Capital Acquisition Corporation's business model?
N/A
What is the highest forecasted price for PV Primavera Capital Acquisition Corporation?
Price targets from Wall Street analysts for PV are not currently available. The stock is trading at $2.47.
What is the lowest forecasted price for PV Primavera Capital Acquisition Corporation?
Price targets from Wall Street analysts for PV are not currently available. The stock is trading at $2.47.
What is the overall PV consensus from analysts for Primavera Capital Acquisition Corporation?
Analyst ratings for PV are not currently available. The stock is trading at $2.47.
How accurate are PV stock price projections?
Stock price projections, including those for Primavera Capital Acquisition Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 9:50 AM UTC